Basel, 13.09.2021 – Around 850 life sciences executives celebrated the reunion at the first live Swiss Biotech Day event since the COVID-19 pandemic began.
The Swiss biotech industry is not letting the COVID-19 pandemic slow it down. This much was evident at the first live Swiss Biotech Day since the pandemic began. With 850 visitors, there were high spirits among the exhibitors and officially 850 visitors at the event hosted by the SBA and organised by BIOCOM AG at the Congress Center Basel.
The positive trend seems to continue this year. “There is enough money in the market,” Jürg Zürcher, partner and co-author of the Swiss Biotech Report at EY, told BIOCOM’s European Biotechnology magazine when asked about the current development of the Swiss biotech industry this year.
It goes without saying that the COVID-19 requirements of the Swiss authorities were rigorously implemented during the event. For example, certificate checks were carried out on visitors and panel guests in accordance with the 3G rule.
In-depth report on european-biotechnology.com